SUWON, South Korea– OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, today announced that the Company’s subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technology.
mCureX, specializing in mRNA vaccines and therapeutics, and ToolGen, having expertise in therapeutic gene-editing technologies, have been in active discussions since their signing of memorandums of understanding in August 2021. The two companies plan to conduct gene corrections in ocular tissues using mCureX’s mRNA technology and ToolGen’s CRISPR/Cas9 gene-editing technology for the treatment of rare hereditary eye diseases.
“mRNA-based CRISPR/Cas9 is a powerful platform that could potentially lead to the development of treatments for incurable diseases,” said Sun Woo Hong, Ph.D., chief executive officer of mCureX. “Once we clinically validate the technology, we plan to expand the indications of treatments to various non-hereditary eye diseases as well.”
